Skip to content

Drug interactions

Efavirenz + Lomitapide

Severity: Contraindicated

Efavirenz and Lomitapide: contraindicated interaction.

Last updated

For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.

Summary

Lomitapide is a sensitive CYP3A4 substrate and exposure can rise markedly with interacting drugs, increasing hepatotoxicity and gastrointestinal adverse effects. Efavirenz is a mixed CYP3A4 modulator and the net effect is uncertain, but the label restricts such combinations.

What this interaction means in plain words

Efavirenz and Lomitapide are not normally used together. Taking them at the same time is expected to cause harm or make one of them unsafe, so a different medicine is usually chosen for one of the two.

Efavirenz belongs to Anti Virals; Lomitapide belongs to Cardiovascular.

Evidence level: Low

Why it happens

Efavirenz modulation of CYP3A4 alters lomitapide metabolism, with potential for increased exposure.

What to do

Avoid the combination and choose a different lipid-lowering strategy or antiretroviral. If lomitapide is essential, monitor liver enzymes closely.

What to ask your pharmacist

  • Is there an alternative to one of these two medicines for me?
  • If both are essential, who is monitoring me and how often?
  • Which symptoms mean I should stop and seek help straight away?

Bring a full list of your medicines, including over-the-counter products, supplements and herbal remedies, to every pharmacy visit.

Pro+ members

Unlock the full page

Create an account and start a Pro+ trial to unlock the full management advice for Efavirenz and Lomitapide, the additional notes, the evidence detail and the whole-prescription interaction checker.

  • Full clinical management advice
  • Additional notes
  • Evidence detail
  • Interaction checker for a whole prescription

Try Pro+ free for 14 days on the web. No card needed.

Frequently asked questions

Can I take Efavirenz with Lomitapide?

MediHelp rates the interaction as contraindicated. Efavirenz and Lomitapide are not normally used together. Taking them at the same time is expected to cause harm or make one of them unsafe, so a different medicine is usually chosen for one of the two. Lomitapide is a sensitive CYP3A4 substrate and exposure can rise markedly with interacting drugs, increasing hepatotoxicity and gastrointestinal adverse effects. Efavirenz is a mixed CYP3A4 modulator and the net effect is uncertain, but the label restricts such combinations.

How serious is the interaction between Efavirenz and Lomitapide?

MediHelp rates it contraindicated, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Avoid the combination and choose a different lipid-lowering strategy or antiretroviral. If lomitapide is essential, monitor liver enzymes closely.

What other medicines interact with Efavirenz?

MediHelp also lists interactions of Efavirenz with, for example, Cobimetinib, Dienogest / estradiol valerate, Dihydroergotamine intranasal. The full list is on the Efavirenz page.

Full monographs, dosing and an interaction checker in the MediHelp app

Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.

Browse A–Z · Drug interactions

Get the app Sign in